How would you approach systemic therapy for a pre-menopausal woman with ER+/PR+/HER2 positive breast cancer who had a local recurrence 6 months after completing adjuvant TCH and a year of trastuzumab + tamoxifen?

Would you consider neoadjuvant or adjuvant treatment and if so, which therapies? Patient initially had pT2N0 disease and recurrent disease is also ER+/PR+/HER2 positive.

Answer from: Medical Oncologist at Community Practice

This patient has high-risk disease. First point: Option 1: Since the cancer recurred 6 months from TCH, I think you can justify using TDM-1 and pertuzumab combination based on I-SPY 2 data (pCR achieved in 52% for women treated with TDM-1 and pertuzumab versus 22% for women treated with tr...

Comments

Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
In a situation like this where there is a local re...

Medical Oncologist at Northwestern Medicine Cancer Center at KishHealth
Stop after a year.

Medical Oncologist at NYU Winthrop Hospital
I will use Trastuzumab DXd based on DESTINY-Breast...

Please select the option that best describes you:

How would you approach systemic therapy for a pre-menopausal woman with ER+/PR+/HER2 positive breast cancer who had a local recurrence 6 months after completing adjuvant TCH and a year of trastuzumab + tamoxifen?

Related Questions